ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Urovant Sciences Ltd

Urovant Sciences Ltd (UROV)

16.24
0.00
(0.00%)
Closed November 03 4:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
16.24
Bid
0.01
Ask
199,999.99
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
16.24
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

UROV Latest News

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting

Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder (OAB) and urge urinary incontinence (UUI) will be featured in a late...

Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant...

Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg

Data from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA® (vibegron) experienced...

Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

Data from a dedicated ambulatory blood pressure study showed once-daily treatment with GEMTESA® was not associated with statistically significant or clinically meaningful effects on blood...

Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results

SEC reviewing preliminary proxy statement for the previously announced merger of the Company with Sumitovant Biopharma Special General Meeting of Shareholders to approve the merger is expected...

Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data & Safety Mon...

Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene...

Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overact...

GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences U.S. commercial launch planned in late-Q1...

Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) P...

Key secondary endpoint of Global Improvement Scale (GIS) showed numerical differences in favor of vibegron versus placebo, however data was not statistically significant Vibegron was generally...

Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study

Extension study demonstrates favorable results in long term treatment of overactive bladder with vibegron, including improvements in incontinence efficacy, quality of life endpoints and with good...

Disney, DraftKings, Palantir, Li Auto: What to Watch When the Stock Market Opens Today

By Mischa Frankl-Duval Here's what we are watching as markets kick into gear Friday. -- U.S. stock futures climbed, suggesting most major indexes are headed for a second week of gains...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VSTEVast Renewable Ltd
$ 4.98
(149.00%)
68.54M
INVZWInnoviz Technologies Ltd
$ 0.096
(96.71%)
22.71k
CDXCChromaDex Corporation
$ 5.87
(68.19%)
37.88M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
TILEInterface Inc
$ 23.24
(33.03%)
2.16M
EPIXESSA Pharma Inc
$ 1.45
(-72.12%)
34.3M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
OSTOstin Technology Group Company Ltd
$ 0.275
(-45.00%)
2.27M
LXRXLexicon Pharmaceuticals Inc
$ 1.23
(-36.92%)
21M
VCIGVCI Global Ltd
$ 0.0583
(-27.58%)
26.57M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
SQQQProShares UltraPro Short QQQ
$ 7.44
(-2.11%)
216.16M
NVDANVIDIA Corporation
$ 135.40
(1.99%)
209.27M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
INTCIntel Corporation
$ 23.20
(7.81%)
173.47M

UROV Discussion

View Posts
Grant Lee Grant Lee 4 years ago
EOY i believe
👍️0
Warrens Warrens 4 years ago
When's the FDA approval?
👍️0
Grant Lee Grant Lee 4 years ago
Wasn't expecting this until after FDA approval, looks like Sumitovant saw it trading so cheap and decided to buyout out early at a discount.
👍️0
Paullee Paullee 4 years ago
BINGO
👍️0
Grant Lee Grant Lee 4 years ago
Finally, Sumitomo, a japanese company, owns 75% of the outstanding shares. Urovant does not need seasoned equity offerings to raise capital because Sumitomo has offered debt financing, preventing dilution. It is most likely Urovant will eventually be bought out fully by Sumitomo as Urovant finishes building out its commercial and market access infrastructure. Sumitomo will benefit from allowing Urovant to build out its own team because of the large equity ownership by the management team. This has allowed for a state of the art team to be constructed, which benefits Sumitomo, which has no United States infrastructure to launch Vibegron.
👍️0
Grant Lee Grant Lee 4 years ago
While Urovant's vibegron is by far the superior asset compared to Astellas' Mirabegron, as seen in the image below. There is still some concern about Urovant's performance entering a market which will soon be filled with generics as well as Myrbetriq. This is a valid concern, however Urovant does have an ace up it's sleeve. Vibegron is crushable. Long term care will be a very important market for Urovant to leverage. It is very common for elderly patients to have issues with OAB, with Vibegron being crushable, Urovant has an incredible advantage compared to other products on the market.

👍️0
Grant Lee Grant Lee 4 years ago
Astellas' myrbetriq achieved $900 MM of sales within its first 5 years on the market. In 2019, Myrbetriq had $1501 MM of sales in the US.
👍️0
Grant Lee Grant Lee 4 years ago
As Astellas' Mirabegron (myrbetriq) is closing in on its exclusivity expiration date, vibegron and Urovant Sciences is positioned very well in the marketplace to pick up their market share. Vibegron is already commercially approved in japan by Kyorin Pharmaceuticals.
👍️0
Paullee Paullee 4 years ago
C C transcript

https://seekingalpha.com/article/4354603-urovant-sciences-ltd-urov-on-q4-2019-results-earnings-call-transcript?part=single
👍️0
Paullee Paullee 4 years ago
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
Business Wire Business Wire•June 18, 2020
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd.

The co-promotion agreement will enable Urovant to leverage Sunovion’s commercial infrastructure to increase efficiency of the planned launch of vibegron. The agreement covers services such as account management, contract operations, third party logistics, and trade and retail distribution.

"Our affiliation with Sunovion through the Sumitomo Dainippon Pharma family of companies allows us to capitalize on the expertise and scale of Sunovion’s operational infrastructure," said Kenton Stewart, SVP of Market Access of Urovant Sciences. "Through our combined efforts, we will accelerate preparations for our anticipated launch of vibegron in the U.S. market."

"We are pleased to enter into this relationship with Urovant," said Thomas Gibbs, SVP and Chief Commercial Officer of Sunovion. "This agreement will enable Urovant to access Sunovion’s well-established commercial capabilities as together we prepare for the launch of this important investigational medicine."
👍️0
Paullee Paullee 4 years ago
Jefferies presentation

http://ir.urovant.com/events-and-presentations
👍️0